Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving The Greenbrier Companies, Inc. and its officers or directors [1]. Financial Performance - On April 7, 2025, Greenbrier reported fiscal Q2 2025 results, with non-GAAP earnings per share of $1.69, missing consensus estimates by $0.09 [3]. - The company reported revenues of $762.1 million, which fell short of consensus estimates by $136.43 million and represented a year-over-year decline of 11.7% [3]. - Following the financial report, Greenbrier's stock price dropped by $5.11 per share, or 11.42%, closing at $39.63 per share on April 8, 2025 [3]. Operational Changes - Greenbrier announced the closure of a facility in Romania, attributing the decision to market conditions and a comprehensive analysis in Europe [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Affirm Holdings, Inc. and its officers or directors [1] Group 1: Company Developments - On March 17, 2025, Klarna announced it would replace Affirm as the exclusive provider of Buy Now, Pay Later loans for Walmart, leading to a significant drop in Affirm's stock price [3] - Following the announcement, Affirm's stock price decreased by $6.38 per share, or 12.74%, closing at $43.70 per share on March 18, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Bitfarms Ltd. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Financial Misstatements - On December 9, 2024, Bitfarms announced that its consolidated financial statements for the fiscal years 2022 and 2023 contained a material error related to the classification of proceeds from digital asset sales, necessitating a restatement [3]. - The company also identified an accounting error concerning the redemption of warrants in 2023, which prompted further adjustments [3]. Group 2: Market Reaction - Following the announcement of the financial misstatements, Bitfarms' stock price fell by $0.13 per share, or 6.07%, closing at $2.01 per share on December 10, 2024 [4]. Group 3: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving HealthEquity, Inc and its officers or directors [1] Financial Performance - On March 18, 2025, HealthEquity reported its financial results for the fourth quarter and fiscal year ending January 31, 2025, with earnings per share that fell short of analyst expectations [3] - The company provided weak guidance for the fiscal year ending January 31, 2026, indicating potential challenges ahead [3] Stock Market Reaction - Following the announcement of disappointing earnings and guidance, HealthEquity's stock price dropped by $17.35 per share, or 17.07%, closing at $84.32 per share on March 19, 2025 [3] Cybersecurity Concerns - HealthEquity's management cited "excess service expense" due to increased cyber threats and fraud attacks, which have been attributed to sophisticated techniques employed by malicious actors [3]

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Ma ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Watsco, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Watsco reported first-quarter 2025 revenue of $1.53 billion, which is a 2% decline year-over-year and below consensus estimates [3]. - The company indicated that the results are influenced by a large-scale product transition due to regulatory changes effective January 1, 2025, impacting approximately 55% of its sales and expected to convert nearly $1 billion of inventory throughout the year [3]. - Following the announcement, Watsco's stock price decreased by $56.76 per share, or 11.28%, closing at $446.40 per share on April 23, 2025 [3].

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Backblaze, Inc. (“Backblaze” or the “Company”) (NASDAQ: BLZE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Backblaze and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 24, 2 ...

Core Viewpoint - ICU Medical, Inc. is under investigation for potential securities fraud and unlawful business practices following a warning letter from the FDA regarding unauthorized changes to its infusion pump products [1][3]. Group 1: FDA Warning and Impact - On April 22, 2025, ICU disclosed that it received a warning letter from the FDA, which cited unauthorized modifications to two of its infusion pump products, labeling them as "adulterated" and "misbranded" [3]. - The FDA's letter indicated that these modifications could significantly affect the functionality of the devices, particularly concerning the infusion delivery profile and alarm functionality, raising safety and efficacy concerns [3]. - Following the news of the FDA warning, ICU's stock price dropped by $6.04 per share, or 4.42%, closing at $130.68 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of ICU investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - T-Mobile US, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results in Q1 2025, which led to a significant drop in stock price [1][3]. Financial Performance - T-Mobile reported adding only 495,000 postpaid phone net customers in Q1 2025, falling short of the consensus expectation of 506,557 net customers [3]. - Following the announcement of these results, T-Mobile's stock price decreased by $29.41 per share, or 11.22%, closing at $232.77 per share on April 25, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of T-Mobile investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].